Cardiovascular Systems Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cardiovascular Systems in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cardiovascular Systems stock.
View analyst ratings for Cardiovascular Systems or view top-rated stocks.

Wall Street analysts have given Cardiovascular Systems a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cardiovascular Systems wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Cardiovascular Systems saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 1,330,000 shares, an increase of 18.8% from the June 30th total of 1,120,000 shares. Based on an average daily volume of 219,200 shares, the days-to-cover ratio is currently 6.1 days. Currently, 3.4% of the shares of the stock are sold short.
View Cardiovascular Systems' Short Interest.

Cardiovascular Systems is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Cardiovascular Systems.

Cardiovascular Systems will be holding an earnings conference call on Wednesday, August 4th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Cardiovascular Systems, Inc. (NASDAQ:CSII) released its quarterly earnings results on Thursday, May, 6th. The medical device company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.10) by $0.05. The medical device company had revenue of $63.30 million for the quarter, compared to analyst estimates of $63.18 million. Cardiovascular Systems had a negative trailing twelve-month return on equity of 8.62% and a negative net margin of 10.11%. The business's quarterly revenue was up 3.4% on a year-over-year basis. During the same period last year, the firm posted ($0.08) earnings per share.
View Cardiovascular Systems' earnings history.

Cardiovascular Systems' stock was trading at $36.32 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CSII shares have increased by 10.9% and is now trading at $40.29.
View which stocks have been most impacted by COVID-19.

Cardiovascular Systems updated its fourth quarter 2021 earnings guidance on Thursday, May, 27th. The company provided EPS guidance of - for the period. The company issued revenue guidance of $67 million-$70 million, compared to the consensus revenue estimate of $69.78 million.

6 brokerages have issued 1-year price targets for Cardiovascular Systems' shares. Their forecasts range from $38.75 to $50.00. On average, they anticipate Cardiovascular Systems' stock price to reach $45.29 in the next year. This suggests a possible upside of 12.4% from the stock's current price.
View analysts' price targets for Cardiovascular Systems or view top-rated stocks among Wall Street analysts.

12 employees have rated Cardiovascular Systems CEO Scott Ward on Glassdoor.com. Scott Ward has an approval rating of 81% among Cardiovascular Systems' employees.

Some companies that are related to Cardiovascular Systems include Abbott Laboratories (ABT), Medtronic (MDT), Intuitive Surgical (ISRG), Stryker (SYK), Becton, Dickinson and (BDX), Edwards Lifesciences (EW), Boston Scientific (BSX), IDEXX Laboratories (IDXX), DexCom (DXCM), ResMed (RMD), Baxter International (BAX), Hologic (HOLX), STERIS (STE), Teleflex (TFX) and Insulet (PODD).
View all of CSII's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiovascular Systems investors own include Gilead Sciences (GILD), AbbVie (ABBV), Advanced Micro Devices (AMD), Medtronic (MDT), Pfizer (PFE), (XEL), ACADIA Pharmaceuticals (ACAD), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK) and The Procter & Gamble (PG).

Cardiovascular Systems trades on the NASDAQ under the ticker symbol "CSII."

Cardiovascular Systems' stock is owned by a number of retail and institutional investors. Top institutional investors include Exchange Traded Concepts LLC (0.23%), Rice Hall James & Associates LLC (0.23%), Alliancebernstein L.P. (0.14%), State of Alaska Department of Revenue (0.07%), MAI Capital Management (0.02%) and 6 Meridian (0.01%). Company insiders that own Cardiovascular Systems stock include Alexander Rosenstein, Erik Paulsen, Martha Goldberg Aronson, Rhonda J Robb, Sandra Sedo and Scott R Ward.
View institutional ownership trends for Cardiovascular Systems.

CSII stock was sold by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, and MAI Capital Management. Company insiders that have sold Cardiovascular Systems company stock in the last year include Alexander Rosenstein, and Sandra Sedo.
View insider buying and selling activity for Cardiovascular Systems or view top insider-selling stocks.

CSII stock was purchased by a variety of institutional investors in the last quarter, including Exchange Traded Concepts LLC, 6 Meridian, Alliancebernstein L.P., State of Alaska Department of Revenue, and Versant Capital Management Inc. Company insiders that have bought Cardiovascular Systems stock in the last two years include Erik Paulsen, Martha Goldberg Aronson, Rhonda J Robb, and Scott R Ward.
View insider buying and selling activity for Cardiovascular Systems or or view top insider-buying stocks.

Shares of CSII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CSII stock can currently be purchased for approximately $40.29.

Cardiovascular Systems has a market capitalization of $1.62 billion and generates $236.54 million in revenue each year. The medical device company earns $-27,240,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis.

Cardiovascular Systems employs 779 workers across the globe.

The official website for Cardiovascular Systems is www.csi360.com.

Cardiovascular Systems is headquartered at 1225 OLD HWY 8 NW, ST. PAUL MN, 55112.

Cardiovascular Systems' mailing address is 1225 OLD HWY 8 NW, ST. PAUL MN, 55112. The medical device company can be reached via phone at 651-259-1600 or via email at [email protected]